Antibody-protein interaction


Last updated: 2021 Nov 20
Total hit(s): 9
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
2019-nCoV RBD binds with SARS-CoV-specific human monoclonal antibody (CR3022) with a KD of 6.3nM. (1) More research is needed to determine the high-resolution structure of the 2019-nCoV RBD and why it could not be detected by these antibodies.
(2) Some of the most potent SARS-CoV-specific neutralising antibodies (e.g., m396, CR3014) targeting the SARS-CoV receptor binding site failed to bind 2019-nCoV spike protein, indicating that new monoclonal antibodies that bind specifically to 2019-nCoV RBD are required.
32065055
(Emerg Microbes Infect)
PMID
32065055
Date of Publishing: 2020
Title Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
Author(s) nameTian X, Li C et al.
Journal Emerg Microbes Infect
Impact factor
5.84
Citation count: 579
Date of Entry 2021 Nov 20


IgA monoclonal antibody, MAb362, competitively blocks SARS-CoV and SARS-CoV-2 spike proteins and ACE2 receptor binding. The binding affinity of IgA and IgG with RBD of SARS-CoV-2 is 0.3nM and 13nM, respectively. The study of interaction of MAb362 with other receptor blocking and neutralising antibodies against SARS-CoV-2 will help in the development of vaccines and prophylactic/therapeutic antibodies to combat future outbreaks caused by this virus family.
32826914
(Nat Commun)
PMID
32826914
Date of Publishing: 2020 Aug 21
Title A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
Author(s) nameEjemel M, Li Q et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 18
Date of Entry 2021 Oct 30


Structural characterization of SARS-CoV-2 spike glycoprotein (RBD to S2 double mutant (rS2d)) constructs. And determing its binding with the antibody CR3022 and human cell receptor ACE2. The spike glycoprotein mutant constructs (rS2d) with double mutation S383C, D985C were developed. The RBD in the rS2d construct is locked in the 'down ' state conformation.
32699321
(Nat Struct Mol Biol)
PMID
32699321
Date of Publishing: 2020 Oct
Title Controlling the SARS-CoV-2 spike glycoprotein conformation
Author(s) nameHenderson R, Edwards RJ et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 43


Structural characterization of SARS-CoV-2 spike glycoprotein (subdomain 1 to S2 quadruple mutant (u1S2q 1 Up RBD)) construct. And determing its binding with the antibody CR3022 and human cell receptor ACE2. The spike glycoprotein mutant construct (u1S2q) with mutation A570L,T572I, F855Y, N856I were developed. The u1S2q 1 Up RBD Spike Protein Trimer were docked with the CR3022 Fab - RBD complex (PDB 6YLA) and potential clashes were observed in between.
32699321
(Nat Struct Mol Biol)
PMID
32699321
Date of Publishing: 2020 Oct
Title Controlling the SARS-CoV-2 spike glycoprotein conformation
Author(s) nameHenderson R, Edwards RJ et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 43


Structural characterization of SARS-CoV-2 spike glycoprotein (subdomain 1 to S2 quadruple mutant (u1S2q 2 Up RBD state)) construct and determing its binding with the antibody CR3022 human cell receptor ACE2 The spike glycoprotein mutant construct (u1S2q) with mutation A570L,T572I, F855Y, N856I were developed. The u1S2q 2 Up RBD Spike Protein Trimer were docked with the CR3022 Fab - RBD complex (PDB 6YLA) and potential clashes were observed in between.
32699321
(Nat Struct Mol Biol)
PMID
32699321
Date of Publishing: 2020 Oct
Title Controlling the SARS-CoV-2 spike glycoprotein conformation
Author(s) nameHenderson R, Edwards RJ et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 43


Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab The spike protein is an attractive candidate for both vaccine development and immunotherapy. As monoclonal antibodies are recognised as potential antivirals,the results in this study suggest that CR3022 could be of immediate utility because the mechanism of neutralization will be unusually resistant to virus escape.
32585135
(Cell Host Microbe)
PMID
32585135
Date of Publishing: 2020 Sep 9
Title Neutralization of SARS-CoV-2 by destruction of the Prefusion Spike
Author(s) nameHuo J, Zhao Y et al.
Journal Cell Host Microbe
Impact factor
10.45
Citation count: 39


Structural characterisation of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal form 1) The binding of ACE2 to the RBD is perturbed by the presence of CR3022.
32585135
(Cell Host Microbe)
PMID
32585135
Date of Publishing: 2020 Sep 9
Title Neutralization of SARS-CoV-2 by destruction of the Prefusion Spike
Author(s) nameHuo J, Zhao Y et al.
Journal Cell Host Microbe
Impact factor
10.45
Citation count: 39


SARS-CoV-2 is neutralized by the binding of CR3022. CR3022 epitope on binding results in fusion-incompetent post-fusion state of the S-protein. CR3022 epitope can be used as a major target for therapeutic antibodies.
32585135
(Cell Host Microbe)
PMID
32585135
Date of Publishing: 2020 Sep 9
Title Neutralization of SARS-CoV-2 by destruction of the Prefusion Spike
Author(s) nameHuo J, Zhao Y et al.
Journal Cell Host Microbe
Impact factor
10.45
Citation count: 39


CR3022 interacts with a conserved epitope away from the receptor binding site when any two RBDs on the trimeric S-protein are in the "up" conformation and slightly rotated. This results in cross reactive binding between SARS-CoV-2 and SARS-CoV. SARS-CoV-2 has a conserved, epitope shared between SARS-CoV-2 and SARS-CoV. The availability of conserved epitopes would allow structure-based design of a SARS-CoV-2 vaccine and also of cross-protective antibody responses against future coronavirus epidemics and pandemics.
32245784
(Science)
PMID
32245784
Date of Publishing: 2020 May 8
Title A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Author(s) nameYuan M, Wu NC et al.
Journal Science
Impact factor
20.57
Citation count: 597